Human pericytes degrade diverse α-synuclein aggregates

PLoS One. 2022 Nov 18;17(11):e0277658. doi: 10.1371/journal.pone.0277658. eCollection 2022.

Abstract

Parkinson's disease (PD) is a progressive, neurodegenerative disorder characterised by the abnormal accumulation of α-synuclein (α-syn) aggregates. Central to disease progression is the gradual spread of pathological α-syn. α-syn aggregation is closely linked to progressive neuron loss. As such, clearance of α-syn aggregates may slow the progression of PD and lead to less severe symptoms. Evidence is increasing that non-neuronal cells play a role in PD and other synucleinopathies such as Lewy body dementia and multiple system atrophy. Our previous work has shown that pericytes-vascular mural cells that regulate the blood-brain barrier-contain α-syn aggregates in human PD brains. Here, we demonstrate that pericytes efficiently internalise fibrillar α-syn irrespective of being in a monoculture or mixed neuronal cell culture. Pericytes cleave fibrillar α-syn aggregates (Fibrils, Ribbons, fibrils65, fibrils91 and fibrils110), with cleaved α-syn remaining present for up to 21 days. The number of α-syn aggregates/cell and average aggregate size depends on the type of strain, but differences disappear within 5 five hours of treatment. Our results highlight the role brain vasculature may play in reducing α-syn aggregate burden in PD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Lewy Body Disease* / metabolism
  • Neurons / metabolism
  • Parkinson Disease* / pathology
  • Pericytes / metabolism
  • alpha-Synuclein / metabolism

Substances

  • alpha-Synuclein

Grants and funding

This work was supported by the Hugh Green Foundation, Ian and Sue Parton. BVD was funded by the Michael J Fox Foundation (16420), the NeuroResearch Charitable Trust and Health Research Council Hercus (21/034). RM lab is supported by France Parkinson and the European Union Joint Programme on Neurodegenerative Disease Research and Agence National de la Recherche (contracts PROTEST-70, ANR-17-JPND-0005-01 and Trans-PathND, ANR- 17-JPND-0002-02). MD is supported through a Programme grant from the Health Research Council of New Zealand (21/730) and the Michael J Fox Foundation (16420). There was no additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or manuscript preparation.